131 related articles for article (PubMed ID: 16282481)
1. Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.
Wurtzer S; Compain S; Benech H; Hance AJ; Clavel F
J Virol; 2005 Dec; 79(23):14815-21. PubMed ID: 16282481
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells.
Olivero OA; Tejera AM; Fernandez JJ; Taylor BJ; Das S; Divi RL; Poirier MC
Mutagenesis; 2005 Mar; 20(2):139-46. PubMed ID: 15784690
[TBL] [Abstract][Full Text] [Related]
3. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
Bouchonnet F; Dam E; Mammano F; de Soultrait V; Henneré G; Benech H; Clavel F; Hance AJ
J Virol; 2005 Jan; 79(2):812-22. PubMed ID: 15613309
[TBL] [Abstract][Full Text] [Related]
4. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
5. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
Kerr SG; Anderson KS
Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
[TBL] [Abstract][Full Text] [Related]
6. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
[TBL] [Abstract][Full Text] [Related]
7. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
[TBL] [Abstract][Full Text] [Related]
8. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
[TBL] [Abstract][Full Text] [Related]
9. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Gao WY; Johns DG; Tanaka M; Mitsuya H
Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
[TBL] [Abstract][Full Text] [Related]
10. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
[TBL] [Abstract][Full Text] [Related]
11. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
12. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
13. Mg2+ dependency of HIV-1 reverse transcription, inhibition by nucleoside analogues and resistance.
Goldschmidt V; Didierjean J; Ehresmann B; Ehresmann C; Isel C; Marquet R
Nucleic Acids Res; 2006; 34(1):42-52. PubMed ID: 16394022
[TBL] [Abstract][Full Text] [Related]
14. Effects of beta-L-3'-azido-3'-deoxythymidine 5'-triphosphate on host and viral DNA polymerases.
Faraj A; El Alaoui AM; Gosselin G; Imbach JL; Morrow C; Sommadossi JP
Antiviral Res; 2000 Aug; 47(2):97-102. PubMed ID: 10996397
[TBL] [Abstract][Full Text] [Related]
15. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
16. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.
Gu Z; Allard B; de Muys JM; Lippens J; Rando RF; Nguyen-Ba N; Ren C; McKenna P; Taylor DL; Bethell RC
Antimicrob Agents Chemother; 2006 Feb; 50(2):625-31. PubMed ID: 16436719
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
[TBL] [Abstract][Full Text] [Related]
18. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Larder BA; Kellam P; Kemp SD
Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
Menéndez-Arias L
Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
